13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      TRIB3 supports breast cancer stemness by suppressing FOXO1 degradation and enhancing SOX2 transcription

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The existence of breast cancer stem cells (BCSCs) is a major reason underlying cancer metastasis and recurrence after chemotherapy and radiotherapy. Targeting BCSCs may ameliorate breast cancer relapse and therapy resistance. Here we report that expression of the pseudokinase Tribble 3 (TRIB3) positively associates with breast cancer stemness and progression. Elevated TRIB3 expression supports BCSCs by interacting with AKT to interfere with the FOXO1-AKT interaction and suppress FOXO1 phosphorylation, ubiquitination, and degradation by E3 ligases SKP2 and NEDD4L. The accumulated FOXO1 promotes transcriptional expression of SOX2, a transcriptional factor for cancer stemness, which in turn, activates FOXO1 transcription and forms a positive regulatory loop. Disturbing the TRIB3-AKT interaction suppresses BCSCs by accelerating FOXO1 degradation and reducing SOX2 expression in mouse models of breast cancer. Our study provides insights into breast cancer development and confers a potential therapeutic strategy against TRIB3-overexpressed breast cancer.

          Abstract

          Cancer stem cells contribute to breast cancer metastasis and recurrence. Here the authors show that TRIB3 enhances breast cancer stemness through interaction with AKT to promote FOXO1 stability, which then increases SOX2 activity.

          Related collections

          Most cited references48

          • Record: found
          • Abstract: found
          • Article: not found

          Forkhead box proteins: tuning forks for transcriptional harmony.

          Forkhead box (FOX) proteins are multifaceted transcription factors that are responsible for fine-tuning the spatial and temporal expression of a broad range of genes both during development and in adult tissues. This function is engrained in their ability to integrate a multitude of cellular and environmental signals and to act with remarkable fidelity. Several key members of the FOXA, FOXC, FOXM, FOXO and FOXP subfamilies are strongly implicated in cancer, driving initiation, maintenance, progression and drug resistance. The functional complexities of FOX proteins are coming to light and have established these transcription factors as possible therapeutic targets and putative biomarkers for specific cancers.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Breast cancer stem cells, cytokine networks, and the tumor microenvironment.

            Many tumors, including breast cancer, are maintained by a subpopulation of cells that display stem cell properties, mediate metastasis, and contribute to treatment resistance. These cancer stem cells (CSCs) are regulated by complex interactions with the components of the tumor microenvironment - including mesenchymal stem cells, adipocytes, tumor associated fibroblasts, endothelial cells, and immune cells - through networks of cytokines and growth factors. Since these components have a direct influence on CSC properties, they represent attractive targets for therapeutic development.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity.

              Glioblastoma, the most aggressive cerebral tumor, is invariably lethal. Glioblastoma cells express several genes typical of normal neural stem cells. One of them, SOX2, is a master gene involved in sustaining self-renewal of several stem cells, in particular neural stem cells. To investigate its role in the aberrant growth of glioblastoma, we silenced SOX2 in freshly derived glioblastoma tumor-initiating cells (TICs). Our results indicate that SOX2 silenced glioblastoma TICs, despite the many mutations they have accumulated, stop proliferating and lose tumorigenicity in immunodeficient mice. SOX2 is then also fundamental for maintenance of the self-renewal capacity of neural stem cells when they have acquired cancer properties. SOX2, or its immediate downstream effectors, would then be an ideal target for glioblastoma therapy.
                Bookmark

                Author and article information

                Contributors
                cuibing@imm.ac.cn
                huzhuowei@imm.ac.cn
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                16 December 2019
                16 December 2019
                2019
                : 10
                : 5720
                Affiliations
                [1 ]ISNI 0000 0000 9889 6335, GRID grid.413106.1, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, , Chinese Academy of Medical Sciences and Peking Union Medical College, ; Beijing, 100050 China
                [2 ]ISNI 0000 0000 9889 6335, GRID grid.413106.1, Institute of Medicinal Biotechnology, , Chinese Academy of Medical Sciences and Peking Union Medical College, ; Beijing, 100050 China
                [3 ]ISNI 0000 0000 9889 6335, GRID grid.413106.1, Institute of Basic Medical Sciences, , Chinese Academy of Medical Sciences and Peking Union Medical College, ; Beijing, 100005 China
                Author information
                http://orcid.org/0000-0002-3719-5601
                http://orcid.org/0000-0001-6214-1384
                http://orcid.org/0000-0002-9903-6980
                http://orcid.org/0000-0001-8374-7801
                Article
                13700
                10.1038/s41467-019-13700-6
                6915745
                31844113
                80495be4-30ca-4d18-9db7-504bdab099f1
                © The Author(s) 2019

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 19 September 2018
                : 13 November 2019
                Funding
                Funded by: National Key R&D Program of China, 2017YFA0205400
                Categories
                Article
                Custom metadata
                © The Author(s) 2019

                Uncategorized
                breast cancer,cancer stem cells,target identification
                Uncategorized
                breast cancer, cancer stem cells, target identification

                Comments

                Comment on this article